At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed invasive non-melanoma skin cancer (NMSC), basal cell carcinoma (BCC) or squamous cell carcinoma (SCC)
- ✓Tumor stage ≥T2 per TNM Classification 8th Edition
- ✓Tumor thickness up to 2cm maximum depth/exophytic growth
- ✓Age ≥65 years
- ✕Histology other than BCC or SCC
- ✕T1 tumor and/or N+ disease
- ✕Resected tumors (R1, R2, or adjuvant indication)
- ✕Tumor invasion into critical areas
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Skin Cancer and Hyperthermia and Radiotherapy - SAHARA a Two-arm, Open-label, Randomized Controlled Phase II Trial
In Brief
A clinical study evaluating Water-filtered infrared-A-hyperthermia (wIRA) hyperthermia combined and Radiotherapy (RT) for Basal Cell Carcinoma and 2 related conditions. Currently recruiting, targeting 100 participants across 4 sites.
Signals
Detailed Summary
The SAHARA trial assesses wether combining ultrahypofractionated accelerated radiotherapy (RT) with hyperthermia is as effective as standard hypofractionated high-dose radiation in treating non-melanoma skin cancer (NMSC).
Study Details
Timeline
Interventions
The wIRA device applies hyperthermia by heating the treatment area (with maximum surface temperature set to 43° C), aiming to make cancer cells more sensitive to radiation therapy for non-melanoma skin cancer combined with radiotherapy.
Radiotherapy is applied.